Psychopharmacology
October 11, 2025
Michelle St Pierre, Elena Argento, Jordyn Cates et al.
Repeated self-administration of small doses of psychedelics, known as microdosing, has been associated with perceived improvements in psychological functioning. However, few studies have examined effects at the daily level. Drawing on data from a naturalistic, prospective, international survey of adults who microdose (N = 1435), we assessed self-reported within-person changes between...
Journal of Psychedelic Studies
October 29, 2024
Pamela Kryskow, Paul Stamets, Joseph T. la Torre et al.
4 citations
Abstract Interest in psychedelic research in the West is surging, however, clinical trials have almost exclusively studied synthetic compounds such as MDMA, ketamine, DMT, LSD, ibogaine, and psilocybin. To date, few clinical trials have utilized whole mushroom/plant material like Psilocybe mushrooms, Iboga, or Ayahuasca. Individuals participating in the Roots To Thrive Psilocybin-Assisted...
bioRxiv
December 15, 2022
Alexander J. Bradshaw, Virginia Ramírez-Cruz, Ali R. Awan et al.
5 citations
preprint
Abstract Psychoactive mushrooms in the genus Psilocybe have immense cultural value and have been used for centuries in Mesoamerica. Despite a recent surge in interest in these mushrooms due to emerging evidence that psilocybin, the main psychoactive compound, is a promising therapeutic for a variety of mental illnesses, their phylogeny and taxonomy remain substantially incomplete. Moreover, the...
Applied and Environmental Microbiology
November 29, 2022
Virginia Ramírez-Cruz, Giuliana Furci, Paul Stamets et al.
29 citations
The therapeutic use of psilocybin, the active ingredient in “magic mushrooms,” is revolutionizing mental health care for a number of conditions, including depression, posttraumatic stress disorder (PTSD), and end-of-life care. This has spotlighted the current state of knowledge of psilocybin, including the organisms that endogenously produce it.
Sci Rep
July 28, 2022
Joseph M. Rootman, Maggie Kiraga, Pamela Kryskow et al.
2 citations
Author Correction: Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls.
Scientific Reports
June 30, 2022
Joseph M. Rootman, Maggie Kiraga, Pamela Kryskow et al.
53 citations
Abstract Psilocybin microdosing involves repeated self-administration of mushrooms containing psilocybin at doses small enough to not impact regular functioning. Microdose practices are diverse and include combining psilocybin with substances such as lion’s mane mushrooms (Hericium erinaceus; HE) and niacin (vitamin-B3). Public uptake of microdosing has outpaced evidence, mandating further...
Scientific Reports
November 18, 2021
Joseph M. Rootman, Pamela Kryskow, Kalin Harvey et al.
78 citations
Abstract The use of psychedelic substances at sub-sensorium ‘ microdoses’, has gained popular academic interest for reported positive effects on wellness and cognition. The present study describes microdosing practices, motivations and mental health among a sample of self-selected microdosers ( n = 4050) and non-microdosers ( n = 4653) via a mobile application. Psilocybin was the most commonly...